EU panel backs approval of Pfizer's leukemia drug Bosulif

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended that Pfizer's Bosulif, or bosutinib, be approved to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia who didn't respond to or can't tolerate other treatments. The drug, a tyrosine kinase inhibitor, was cleared by the FDA in September.

View Full Article in:

Pharmaceutical Business Review Online · Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Regulatory Affairs Specialist
Becton Dickinson
Franklin Lakes, NJ
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
President/Chief Executive Officer
MedCost
Winston-Salem, NC